4/A: Cumberland Pharmaceuticals Director Corrects Stock Acquisition Report
SEC Filing Amendment
Caroline Young, a director at Cumberland Pharmaceuticals, amends a previous SEC filing to correct the number of shares acquired on March 25, 2024.
Summary
- Caroline Young, a director of Cumberland Pharmaceuticals, filed an amendment to a Form 4, initially submitted on March 26, 2024.
- The amendment corrects the number of shares acquired on March 25, 2024.
- The original filing incorrectly stated that 1,000 shares were acquired, but the correct number is 2,500 shares.
- This reflects an increase of 1,500 shares from the originally reported amount.
- The shares were acquired at a price of $1.71 per share.
- Following the transaction, Ms. Young beneficially owns 31,318 shares of Cumberland Pharmaceuticals.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing correcting a minor error, so it has a neutral sentiment.
Industry Context
This filing is a routine disclosure related to insider trading activities, which are closely monitored by regulators and investors to ensure fair market practices.
Key Dates
| Date | Description |
|---|---|
| 03/25/2024 | Date of stock acquisition |
| 03/26/2024 | Date of original Form 4 filing |
| 01/30/2025 | Date of signature on the amended form |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.